ECSP14028079A - DELAYED RELEASE DRUG FORMULATION (2) - Google Patents

DELAYED RELEASE DRUG FORMULATION (2)

Info

Publication number
ECSP14028079A
ECSP14028079A ECIEPI201428079A ECPI201428079A ECSP14028079A EC SP14028079 A ECSP14028079 A EC SP14028079A EC IEPI201428079 A ECIEPI201428079 A EC IEPI201428079A EC PI201428079 A ECPI201428079 A EC PI201428079A EC SP14028079 A ECSP14028079 A EC SP14028079A
Authority
EC
Ecuador
Prior art keywords
polymeric material
core
inner layer
drug
delayed release
Prior art date
Application number
ECIEPI201428079A
Other languages
Spanish (es)
Inventor
Thomas Buser
Frédéric Jean-Claude Goutte
Gonzalez Roberto Carlos Bravo
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP12166110.2A external-priority patent/EP2659881B1/en
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of ECSP14028079A publication Critical patent/ECSP14028079A/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La liberación retardada de un fármaco al colon se logra de una formulación de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo. El núcleo comprende un fármaco y un recubrimiento que comprende una capa interior y al menos una capa entre el núcleo y la capa exterior seleccionada del grupo que consiste de una capa de aislamiento y una capa interior. La capa exterior comprende una mezcla de un primer material polimérico que es susceptible a ataques por parte de la bacteria colónica, y un segundo material polimérico que tiene un umbral de pH a aproximadamente pH 5 o más alto. La capa interior comprende un tercer material polimérico que es soluble en el fluido intestinal o en el fluido gastrointestinal, tal tercer material polimérico se selecciona de ácido policarboxílico al menos parcialmente neutralizado y un polímero no iónico. En modalidades en donde el tercer material polimérico es un polímero no iónico, la capa interior comprende al menos un agente amortiguador y una base. La capa de aislamiento comprende un polímero no iónico que es soluble en el fluido intestinal o fluido gastrointestinal. El exterior es un medio acuoso con un segundo material polimérico en un medio orgánico. Las ventajas de las formulaciones de acuerdo con la presente invención incluyen la liberación acelerada del fármaco cuando se expone a condiciones colónicas y la reducción o eliminación del efecto de los alimentos y/o alcohol en la liberación del fármaco después de la admiDelayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and a coating comprising an inner layer and at least one layer between the core and the outer layer selected from the group consisting of an insulating layer and an inner layer. The outer layer comprises a mixture of a first polymeric material that is susceptible to attack by colonic bacteria, and a second polymeric material that has a pH threshold at about pH 5 or higher. The inner layer comprises a third polymeric material that is soluble in intestinal fluid or gastrointestinal fluid, such third polymeric material is selected from at least partially neutralized polycarboxylic acid and a non-ionic polymer. In embodiments where the third polymeric material is a non-ionic polymer, the inner layer comprises at least one damping agent and a base. The isolation layer comprises a nonionic polymer that is soluble in intestinal fluid or gastrointestinal fluid. The exterior is an aqueous medium with a second polymeric material in an organic medium. Advantages of formulations according to the present invention include accelerated drug release when exposed to colonic conditions and reduction or elimination of the effect of food and / or alcohol on drug release after administration.

ECIEPI201428079A 2012-04-30 2014-11-25 DELAYED RELEASE DRUG FORMULATION (2) ECSP14028079A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261640217P 2012-04-30 2012-04-30
EP12166110.2A EP2659881B1 (en) 2012-04-30 2012-04-30 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
ECSP14028079A true ECSP14028079A (en) 2015-12-31

Family

ID=54196716

Family Applications (2)

Application Number Title Priority Date Filing Date
ECIEPI201428079A ECSP14028079A (en) 2012-04-30 2014-11-25 DELAYED RELEASE DRUG FORMULATION (2)
ECIEPI201428077A ECSP14028077A (en) 2012-04-30 2014-11-25 DELAYED RELEASE DRUG FORMULATION (1)

Family Applications After (1)

Application Number Title Priority Date Filing Date
ECIEPI201428077A ECSP14028077A (en) 2012-04-30 2014-11-25 DELAYED RELEASE DRUG FORMULATION (1)

Country Status (10)

Country Link
JP (2) JP6700220B2 (en)
CL (2) CL2017001989A1 (en)
CU (2) CU24343B1 (en)
CY (1) CY1121470T1 (en)
EC (2) ECSP14028079A (en)
HK (3) HK1244435B (en)
HR (3) HRP20190470T1 (en)
IL (2) IL235283A (en)
PH (3) PH12017502369A1 (en)
ZA (1) ZA201407675B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3662902A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
CN113493220A (en) * 2020-04-02 2021-10-12 杨洋 Hollow metal oxide microsphere, preparation method thereof and drug sustained-release application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
SI2152250T1 (en) * 2007-05-07 2020-06-30 Evonik Operations Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
EP2659881B1 (en) * 2012-04-30 2017-11-29 Tillotts Pharma Ag A delayed release drug formulation

Also Published As

Publication number Publication date
ZA201407675B (en) 2016-05-25
JP2017145268A (en) 2017-08-24
PH12018500304A1 (en) 2018-09-24
PH12018500304B1 (en) 2018-09-24
CU20160014A7 (en) 2016-04-25
CU24342B1 (en) 2018-05-08
IL235282A (en) 2017-09-28
HRP20190470T1 (en) 2019-05-17
CU20160026A7 (en) 2016-05-30
PH12017502369A1 (en) 2020-09-28
JP6700220B2 (en) 2020-05-27
CL2017001989A1 (en) 2018-03-16
HK1202267A1 (en) 2015-09-25
JP2017145267A (en) 2017-08-24
HK1244435B (en) 2019-10-25
HRP20192210T1 (en) 2020-02-21
CY1121470T1 (en) 2020-05-29
HRP20190727T1 (en) 2019-06-14
PH12018501311A1 (en) 2020-09-14
HK1202266A1 (en) 2015-09-25
CU24343B1 (en) 2018-05-08
CL2017001990A1 (en) 2018-03-16
ECSP14028077A (en) 2015-12-31
IL235283A (en) 2017-09-28
JP6626470B2 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
CR20190245A (en) A delayed release drug formulation
CU20160055A7 (en) FORMULATION OF DELAYED RELEASE DRUG
ECSP14028079A (en) DELAYED RELEASE DRUG FORMULATION (2)
CU20140124A7 (en) FORMULATION OF DELAYED RELEASE DRUG
PE20160211A1 (en) DELAYED RELEASE DRUG FORMULATION